financial results
Sanofi lowers Q3 sales figures from 2015
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cipro, Plavix, Sanofi, financial results
Sanofi lowered its aggregate sales figure for Q3 2016 from €9.59 billion to €9.46 billion ahead of the release of …
Valeant stock rises despite weak Q2 results
August 10, 2016Research and Development, Sales and Marketing Valeant, financial results
Valeant Pharmaceuticals’ share price in pre-market trading has risen 7.44% to $24.12 in the wake of its Q2 results announcement. …
Merck Q2 results beat analyst estimates
August 4, 2016Medical Communications, Sales and Marketing Merck, financial results
Germany pharmaceutical firm Merck has announced its fiscal results for Q2 2016, beating analyst estimates with earnings before interest, taxes, …
Amgen raises 2016 outlook after Q1 earnings boost
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Enbrel, etanercept, financial results, financials, sales rise
Amgen (NASDAQ: AMGN) has upgraded their 2016 outlook after posting an increase of 10% in revenues for the first quarter …
Pfizer revenues down, but above expectations
February 3, 2016Research and Development, Sales and Marketing Ian Read, Pfizer, financial results, income, profits, revenue, sales
Pfizer’s revenues took a hit from generic competition on former blockbusters, but the world’s new largest drugmaker still managed to …
Novartis braces for cuts after mixed 2015 performance
January 28, 2016Sales and Marketing Novartis, financial results, revenue, sales
Net sales at Novartis fell by 5% in 2015 – prompting the company to make billion-dollar changes to its business …
Johnson & Johnson hit by fall in 2015 sales
January 27, 2016Research and Development, Sales and Marketing Janssen, Johnson and Johnson, financial results, revenue, sales
Full year sales at the healthcare giant Johnson & Johnson fell by 6% in 2015, to just over $70 billion, …
Merck achieves 7% sales growth in Q3 2015
November 12, 2015Sales and Marketing Merck, Rebif, financial results
German pharma group Merck has earned a 7% bump in its sales, and a 10% boost in earnings before deductions, …
Top 5 pharma companies’ Q3 results
November 6, 2015Medical Communications, Sales and Marketing financial results, revenue, sales
The leading pharma players have been able to report largely positive financial results to their shareholders in the third quarter …
AstraZeneca acquires ZS Pharma for $2.7bn, announces Q3 results
November 6, 2015Medical Communications AstraZeneca, M&A, MA, ZS Pharma, ZS-9, acquisitions, financial results, hyperkalaemia, mergers
AstraZeneca has announced its acquisition of ZS Pharma for an all-cash total of $2.7 billion. In the latest mega-money deal …
GSK plots return to growth with launch of 20 new drugs by 2020
November 4, 2015Research and Development, Sales and Marketing GSK, Sir Andrew Witty, financial results, product pipeline
GSK has set out plans to boost its flagging performance with the launch of up to 20 new drugs by …
Pfizer approached GSK for takeover before Allergan
November 4, 2015Research and Development, Sales and Marketing Allergan, GSK, Pfizer, financial results, product pipeline
Pfizer had a takeover approach rejected by fellow pharma giant GlaxoSmithKline, before turning its attentions to Allergan, it has emerged. …
Sales up at MSD while Keytruda hits survival target in late-stage trial
October 28, 2015Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab
Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …
Roche buoyed by 6% sales growth
October 22, 2015Sales and Marketing Roche, financial results
Roche has reported strong sales growth for the first nine months of 2015 and revised its sales outlook to reflect …
Revenues up at Biogen – but job losses planned
October 22, 2015Biogen, financial results, job losses, redundancies
Despite lower than predicted sales of its top-selling products, Biogen has achieved $2.8 billion in revenues in the third quarter …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
